Published in J Virol on February 01, 2000
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol (2003) 2.36
High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A (2001) 2.32
Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog (2011) 1.77
Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS (2011) 1.63
Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res (2009) 1.25
Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol (2009) 1.04
Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog (2011) 1.00
A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads. J Infect Dis (2015) 0.88
T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). Clin Diagn Lab Immunol (2000) 0.78
Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus. Immunology (2002) 0.78
Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides. Immunogenetics (2003) 0.77
The interplay between the X-DING-CD4, IFN-α and IL-8 gene activity in quiescent and mitogen- or HIV-1-exposed PBMCs from HIV-1 elite controllers, AIDS progressors and HIV-negative controls. Innate Immun (2013) 0.77
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 10.03
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 10.02
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A (1996) 4.11
Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med (1997) 4.01
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.74
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Human immunodeficiency virus infection of human-PBL-SCID mice. Science (1991) 2.77
CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med (1997) 2.49
Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol (1996) 2.32
CD4+ but not CD8+ cells are essential for allorejection. J Exp Med (1996) 1.72
Host factors in the pathogenesis of HIV disease. Immunol Rev (1997) 1.64
Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology (1995) 1.55
Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis (1995) 1.53
Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retroviruses (1995) 1.49
Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood (1997) 1.40
Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J Virol (1996) 1.37
Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses (1999) 1.24
Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection. J Infect Dis (1999) 1.23
Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol (1997) 0.97
HIV-1-specific production of IFN-gamma and modulation by recombinant IL-2 during early HIV-1 infection. J Immunol (1988) 0.92
Chemokine receptor CCR5 genotype influences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice. J Virol (1997) 0.90
Cell-mediated immune response of macaques immunized with low doses of simian immunodeficiency virus (SIV). J Biotechnol (1996) 0.85
The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy. J Immunol (1995) 0.84
Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. AIDS (1996) 0.81
Infiltrating cells in mouse cardiac allografts after anti-CD4 monoclonal antibody treatment. Transplant Proc (1995) 0.79
The sequence of the human genome. Science (2001) 101.55
The metagenomics RAST server - a public resource for the automatic phylogenetic and functional analysis of metagenomes. BMC Bioinformatics (2008) 29.20
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med (1999) 7.77
A methodology to migrate the gene ontology to a description logic environment using DAML+OIL. Pac Symp Biocomput (2003) 7.04
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science (1997) 6.75
Takayasu arteritis. Ann Intern Med (1994) 5.94
Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. BMJ (2000) 5.43
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Evolution of organic aerosols in the atmosphere. Science (2009) 4.82
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol (1991) 4.63
Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med (1995) 4.06
Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol (2000) 3.83
HIV seroprevalence in newborns in New York State. JAMA (1989) 3.82
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Design of a compartmentalized shotgun assembler for the human genome. Bioinformatics (2001) 3.55
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
The nucleotide sequence of dengue type 4 virus: analysis of genes coding for nonstructural proteins. Virology (1987) 3.51
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med (1997) 3.40
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol (1997) 2.98
Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood (2001) 2.87
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med (1996) 2.86
Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med (1997) 2.79
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med (1991) 2.75
General practitioners with special clinical interests. Clin Med (2001) 2.61
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis (1994) 2.60
Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol (1999) 2.58
HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A (2001) 2.54
Ultrasensitive magnetic biosensor for homogeneous immunoassay. Proc Natl Acad Sci U S A (2000) 2.52
Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol (1996) 2.49
Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J Exp Med (1993) 2.49
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet (1998) 2.45
Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci U S A (2001) 2.41
Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol Cell Biol (1992) 2.39
Genetic polymorphism in CX3CR1 and risk of HIV disease. Science (2000) 2.38
Testing the raters: inter-rater reliability of standardized anaesthesia simulator performance. Can J Anaesth (1997) 2.37
Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J Biol Chem (1994) 2.34
Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res (2001) 2.33
A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med (1999) 2.32
High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A (2001) 2.32
Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. Mol Biol Evol (1999) 2.32
Food choice: a conceptual model of the process. Appetite (1996) 2.25
Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A (2000) 2.23
CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol (2001) 2.21
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A (2000) 2.20
Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med (1999) 2.20
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood (2001) 2.15
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum (1993) 2.14
Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet (1989) 2.12
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med (1993) 2.11
Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. J Biol Chem (1993) 2.08
Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. J Biol Chem (1995) 2.08
Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem (1996) 2.04
Random distribution of mixed species malaria infections in Papua New Guinea. Am J Trop Med Hyg (2000) 2.04
Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. J Immunol (1990) 2.03
HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology (1997) 2.02
An ontology for bioinformatics applications. Bioinformatics (1999) 2.00
Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut (2003) 1.98
Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol (2001) 1.97
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res (1994) 1.87
Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr (1993) 1.86
Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol (2000) 1.86
B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med (2000) 1.79
Histological appearances of the gastric mucosa 15--27 years after partial gastrectomy. J Clin Pathol (1979) 1.79
Molecular mimicry and the generation of host defense protein diversity. Cell (1993) 1.78
Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem (1995) 1.75
The chemokine macrophage-inflammatory protein-1 alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol (2000) 1.75
Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13. Int J Radiat Oncol Biol Phys (2000) 1.71